Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV1-BMP3 is an adeno-associated virus serotype 1 (AAV1) vector-based gene therapy designed to overexpress Bone Morphogenetic Protein 3 (BMP3) in lung tissue. Developed by researchers at the Icahn School of Medicine at Mount Sinai and Virginia Tech, it is being investigated for the treatment of pulmonary arterial hypertension (PAH). BMP3 is a member of the transforming growth factor-beta (TGF-β) superfamily that is downregulated in PAH. By restoring BMP3 levels, the therapy aims to rebalance signaling pathways by activating the protective BMP/Smad1/5/8 axis and suppressing the pro-fibrotic TGF-β/Smad2/3 axis, thereby attenuating pulmonary vascular remodeling and right ventricular dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV1-BMP3.